I agree it seems glaringly obvious that the remaining x 3 will have success, hard to see how there would be different side effects similarly sized groups for each trail.
Furthermore re phase 3, Jon seemed extremely confident that there is really high chance of success moving forward from this point from PMS based on phase 2 data being better that what could have been wished for!
Ann: Completion of enrolment in Neuren's Angelman P2 trial, page-8
-
- There are more pages in this discussion • 45 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$14.07 |
Change
-0.400(2.76%) |
Mkt cap ! $1.798B | |||
| Open | High | Low | Value | Volume |
| $14.47 | $14.53 | $13.99 | $7.843M | 552.7K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 2150 | $14.06 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.10 | 1129 | 2 |
View Market Depth
| Last trade - 16.10pm 03/09/2024 (20 minute delay) ? |
| NEU (ASX) Chart |